Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001016955 | SCV001177966 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-11-05 | criteria provided, single submitter | clinical testing | The p.Y3379S variant (also known as c.10136A>C), located in coding exon 26 of the BRCA2 gene, results from an A to C substitution at nucleotide position 10136. The tyrosine at codon 3379 is replaced by serine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004689956 | SCV005185656 | uncertain significance | not specified | 2024-05-16 | criteria provided, single submitter | clinical testing |